Financial Data and Key Metrics Changes - The company reported third quarter revenue of $349 million, reflecting a 4% growth on a reported basis and flat organic growth [7] - Adjusted earnings per share increased by 14% to $1.19, indicating meaningful earnings growth and margin expansion [8] - Adjusted gross margin for the third quarter was 57.7%, up 240 basis points year-over-year, driven by favorable volume growth and improving portfolio mix [31] - Adjusted operating income for the third quarter was $89.4 million, representing a 25.7% margin, a record for the company [33] Business Line Data and Key Metrics Changes - Hospital revenue grew 24% on a reported basis in the third quarter and 28% year-to-date, with organic growth of 12% and 14% respectively [10] - Blood Management Technologies, the largest hospital franchise, saw revenue growth of 10% in the quarter, driven by sustained market growth and share gains [10] - Hemostasis management experienced 26% revenue growth in the U.S., driven by improved device utilization [11] - Plasma revenue declined 9% in the quarter due to the planned CSL transition, but U.S. disposables revenue grew when excluding CSL [17][22] Market Data and Key Metrics Changes - Revenue growth in Europe for plasma was in double digits, driven by share gains and a robust collections environment [18] - The company signed long-term agreements with BioLife and Grifols, reinforcing its market position and innovation in plasma collections [19][85] - International demand for source plasma is expanding, with the company selected as the exclusive supplier for the Japanese Red Cross [23] Company Strategy and Development Direction - The divestiture of the whole blood business aligns resources to higher margin, higher growth opportunities [9][36] - The company is focused on innovation and technology upgrades to drive market share and improve profitability [20][27] - The updated guidance for hospital revenue is set at 24% to 26% on a reported basis and 12% to 14% on an organic basis [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the foundation being built for transformational growth, despite external market challenges [9][25] - The company anticipates strong earnings performance and has tightened its adjusted EPS guidance range to $4.50 to $4.70 [36] - Management noted that while external disruptions are challenging, the company has adapted and driven progress [26] Other Important Information - Cash on hand at the end of the quarter was $320.8 million, up $142 million since the beginning of the fiscal year [40] - The company expects to finish fiscal '25 with strong free cash flow, updating guidance to a range of $120 million to $140 million [39] Q&A Session Summary Question: Can you walk through the CSL contribution in the quarter? - Management confirmed that CSL's performance is on track with initial guidance, with a 70-30 split in revenue realization [47] Question: What is the outlook for VASCADE? - Management acknowledged competition and internal resource allocation issues but expressed confidence in future performance [60][106] Question: Can you provide details on the BioLife and Grifols contracts? - Management indicated these are long-duration contracts (5 to 7 years) with tiered pricing that benefits both parties [85] Question: What are the expectations for plasma collections growth? - Management anticipates mid to high single-digit growth in fractionation capacity through 2032, indicating a strong market demand [92] Question: How will the divestiture of Whole Blood impact margins? - Management expects a 30 to 40 basis points improvement in operating margin from the divestiture [123]

Haemonetics (HAE) reported $348.54 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 3.7%. EPS of $1.19 for the same period compares to $1.04 a year ago.The reported revenue represents a surprise of -1.30% over the Zacks Consensus Estimate of $353.15 million. With the consensus EPS estimate being $1.19, the company has not delivered EPS surprise.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.09 per share when it actually produced earnings of $1.12, delivering a surprise of 2.75%.Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com | | 3rd Quarter | | 2025 | YTD 2025 | | | --- | --- | --- | --- | --- | --- | | n Revenue, increase | $349 | million, | 4% | $1,030 | million, 7% | | 1 n Organic revenue increase | | —% | | 2% | | | n Earnings per diluted share | | $0.74 | | $2.14 | | | n Adjusted earnings per diluted sha ...

Financial release accessible onlineBOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Tele ...

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, ...

Haemonetics (HAE) recently completed the sale of its whole blood assets to GVS, S.p.A ("GVS"), a leading provider of advanced filtration solutions for highly critical applications. With this development, GVS now has the company’s portfolio of proprietary whole blood collection, processing and filtration solutions, along with its manufacturing facility in Covina, CA and related equipment and assets at its Tijuana, Mexico manufacturing site.The transaction was announced last month and comprises a total cash c ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemone ...

BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...